{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:22:05Z","timestamp":1740162125199,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","award":["number CP2_10\/2018, PLAGENCELL","number CP2_10\/2018, PLAGENCELL","number CP2_10\/2018, PLAGENCELL"],"award-info":[{"award-number":["number CP2_10\/2018, PLAGENCELL","number CP2_10\/2018, PLAGENCELL","number CP2_10\/2018, PLAGENCELL"]}],"id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["ISM project code: 21147","ISM project code: 21147","ISM project code: 21147"],"award-info":[{"award-number":["ISM project code: 21147","ISM project code: 21147","ISM project code: 21147"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amgen (Thousand Oaks, CA) Fondazione per la Ricerca Ospedale Maggiore"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01057-z","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:02:24Z","timestamp":1714122144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6789-5123","authenticated-orcid":false,"given":"Giuseppe","family":"Gritti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Lussana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Landi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Rondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Putelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ballardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Quaresmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Paganessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pavoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Capelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9e","family":"Golay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martino","family":"Introna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"1057_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2016.12.007","volume":"53","author":"T Robak","year":"2017","unstructured":"Robak T, Stilgenbauer S, Tedeschi A. Front-line treatment of CLL in the era of novel agents. Cancer Treat Rev. 2017;53:70\u201378.","journal-title":"Cancer Treat Rev"},{"key":"1057_CR2","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Van Der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood. 2014;123:2944\u201352.","journal-title":"Blood"},{"key":"1057_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2010.89","volume":"24","author":"L Ysebaert","year":"2010","unstructured":"Ysebaert L, Gross E, K\u00fchlein E, Blanc A, Corre J, Fourni\u00e9 JJ, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: Implication for maintenance immunotherapy. Leukemia. 2010;24:1310\u20136.","journal-title":"Leukemia"},{"key":"1057_CR4","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1038\/bcj.2015.86","volume":"5","author":"H Saito","year":"2015","unstructured":"Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 2015;5:e362\u20132.","journal-title":"Blood Cancer J"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1634\/stemcells.18-1-10","volume":"18","author":"CL Mackall","year":"2000","unstructured":"Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells. 2000;18:10\u201318.","journal-title":"Stem Cells"},{"key":"1057_CR6","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.4049\/jimmunol.1401550","volume":"193","author":"J Golay","year":"2014","unstructured":"Golay J, D\u2019Amico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, et al. A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy. J Immunol. 2014;193:4739\u201347.","journal-title":"J Immunol"},{"key":"1057_CR7","doi-asserted-by":"publisher","unstructured":"Capelli C, Frigerio S, Lisini D, Nava S, Gaipa G, Belotti D et al. A comprehensive report of long-term stability data for a range ATMPs: a need to develop guidelines for safe and harmonized stability studies. Cytotherapy 2022. https:\/\/doi.org\/10.1016\/j.jcyt.2021.12.004.","DOI":"10.1016\/j.jcyt.2021.12.004"},{"key":"1057_CR8","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1182\/blood-2010-07-299321","volume":"117","author":"P Christopoulos","year":"2011","unstructured":"Christopoulos P, Pfeifer D, Bartholom\u00e9 K, Follo M, Timmer J, Fisch P, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 2011;117:3836\u201346.","journal-title":"Blood"},{"key":"1057_CR9","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","volume":"93","author":"R Garc\u00eda Mu\u00f1oz","year":"2014","unstructured":"Garc\u00eda Mu\u00f1oz R, Izquierdo-Gil A, Mu\u00f1oz A, Roldan-Galiacho V, Rabasa P, Panizo C. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 2014;93:1879\u201387.","journal-title":"Ann Hematol"},{"key":"1057_CR10","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-09-0418","volume":"15","author":"AP Rapoport","year":"2009","unstructured":"Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, et al. Rapid immune recovery and graft-versus-host disease - Like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res. 2009;15:4499\u2013507.","journal-title":"Clin Cancer Res"},{"key":"1057_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jcyt.2021.11.004","volume":"24","author":"E Gotti","year":"2022","unstructured":"Gotti E, Tettamanti S, Zaninelli S, Cuofano C, Cattaneo I, Rotiroti MC, et al. Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use: GMP-compliant polyclonal T cell expansion in G-Rex. Cytotherapy. 2022;24:334\u201343.","journal-title":"Cytotherapy"},{"key":"1057_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2022.02.001","volume":"108","author":"I Can","year":"2022","unstructured":"Can I, Cox MJ, Siegler EL, Sakemura R, Kenderian SS. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Exp Hematol. 2022;108:1\u20137.","journal-title":"Exp Hematol"},{"key":"1057_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.20.01564","volume":"39","author":"F Lussana","year":"2021","unstructured":"Lussana F, Gritti G, Rambaldi A. Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell? redirected bispecific antibodies. J Clin Oncol. 2021;39:444\u201355.","journal-title":"J Clin Oncol"},{"key":"1057_CR14","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1182\/blood-2022-165448","volume":"140","author":"F Lussana","year":"2022","unstructured":"Lussana F, Magnani CF, Gaipa G, Galimberti S, Gritti G, Belotti D, et al. Final results of phase I\/II study of donor-derived CAR T cells engineered with sleeping beauty in pediatric and adult patients with B-cell acute lymphoblastic leukemia relapsed post-HSCT. Blood. 2022;140:4568\u20139.","journal-title":"Blood"},{"key":"1057_CR15","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1172\/JCI138473","volume":"130","author":"CF Magnani","year":"2020","unstructured":"Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, et al. Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Investig. 2020;130:6021\u201333.","journal-title":"J Clin Investig"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01057-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:02:29Z","timestamp":1714122149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01057-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01057-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"24 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GG reports consultancy fees from Genmab, Roche, Abbvie, Ideogen, Kite-Gilead, Takeda, and travel support from Gilead Kite, Janssen, Beigene. AR reports consultancy fees from Amgen, Pfizer, Novartis, Kite-Gilead, Jazz, Astellas, Abbvie, Incyte, Omeros, Celgene BMS, Sanofi. FL reports consultancy fees from Amgen, Pfizer, Incyte, Bristol Myers Squibb, AbbVie, Clinigen. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the competing health authority, by the Ethics Committee and was registered with access number NCT03823365. An ancillary biological study was approved to prolong the assessment of immunologic parameters. Patients, or their legal representative, provided written consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"73"}}